Skip to main content
Evidence Snapshot

Mitogen-activated protein kinase 1

CHEMBL4040 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4040
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase 1 as ChEMBL target CHEMBL4040, mapped to UniProt P28482. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4040
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P28482
Mitogen-activated protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mitogen-activated protein kinase 1 matters

As of 2026-09-13

Mitogen-activated protein kinase 1 is reviewed as Mitogen-activated protein kinase 1 (UniProt P28482); Mitogen-activated protein kinase 1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 24434 compounds, and 1003 assays, with lead potency reaching pChEMBL 11.0.

Disease context
neoplasm

Mitogen-activated protein kinase 1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MK-8353, RAVOXERTINIB, ULIXERTINIB.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include MK-8353, RAVOXERTINIB, ULIXERTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 24434 compounds, and 1003 assays for this target. The dominant activity type is IC50. CHEMBL3608588 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3608588 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mitogen-activated protein kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P28482, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

24434
Total Compounds
1003
Total Assays
16
Approved Drugs
IC50: 9017.0, KI: 1743.0, EC50: 2.0, KD: 456.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3608588
 11.0 IC50 —
No preferred name
CHEMBL4108345
 11.0 IC50 —
No preferred name
CHEMBL4114147
 11.0 IC50 —
No preferred name
CHEMBL4109252
 11.0 IC50 —
No preferred name
CHEMBL3957670
 11.0 IC50 —

Approved Drugs

Structure Compound First Approval
TIVOZANIB
CHEMBL1289494
 2017
NALFURAFINE
CHEMBL267495
 2009
SORAFENIB
CHEMBL1336
 2005
ZAFIRLUKAST
CHEMBL603
 1996
TANNIC ACID
CHEMBL506247
 1982
ISOTRETINOIN
CHEMBL547
 1982
TRETINOIN
CHEMBL38
 1971
HEXACHLOROPHENE
CHEMBL496
 1949
TRIBROMSALAN
CHEMBL24944
 —
BITHIONOL
CHEMBL290106
 —
3,3',4',5-TETRACHLOROSALICYLANILIDE
CHEMBL291338
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4040